Descrição

Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification.

Figure 18

Chart

Source Paper

Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) on Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study.

Nutrients (2022)

PMID: 35631156

DOI: 10.3390/nu14102015

Cite This Figure

![Figure 18: Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification.]()

> Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." *Nutrients*, 2022. PMID: [35631156](https://pubmed.ncbi.nlm.nih.gov/35631156/)

<figure>
  <img src="" alt="Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification." />
  <figcaption>Figure 18. Summary analysis from the GTB1 probiotic trial showing the relationship between gut microbiota modulation and IBS-D symptom outcomes. The findings support the potential role of Lactiplantibacillus plantarum in managing diarrhea-predominant IBS through microbiome modification.<br>  Source: Kyoungmi Jung et al. "Effect of Oral Intake of Lactiplantibacillus plantarum APsulloc 331261 (GTB1TM) ." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/35631156/">35631156</a></figcaption>
</figure>

Evidências Relacionadas

Lactobacillus plantarum para Irritable Bowel Syndrome (IBS)

Nota B · 5 estudos